Press Releases
March 12, 2024
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24
February 15, 2024
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
February 1, 2024
Panbela Announces Closing of Approximately $9.0 Million Public Offering
January 30, 2024
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
January 29, 2024
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
January 25, 2024
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
Exceeding Anticipated Timelines with Accelerated Momentum
- Interim Data Analysis Anticipated in Mid-2024
- Expects Full Enrollment by Q1 2025
January 18, 2024
Panbela Announces Publication of Clinical Data: A New Approaches to Neuroblastoma Therapy Trial
Panbela Announces Publication of Clinical Data Titled:
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
- A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.
January 16, 2024
Panbela Announces 1-for-20 Reverse Stock Split Effective 1/18/24
December 21, 2023
Panbela Announces Exercise of Warrants, Issuance of New Warrants in Private Placement for $2M Gross Proceeds Priced At-the-Market
December 18, 2023
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
Events & Presentations